Immune Globulin Articles
Canadian scientists are working on an intravenous treatment for Alzheimer’s that could halt the progression of the disease and improve cognitive functions.
The U.S.Food and Drug Administration has approved subcutaneous Gammagard Liquid 10% for patients with primary immunodeficiency.
SL Behring has developed a pharmacokinetic model that shows how the body absorbs, distributes, metabolizes and eliminates immunoglobulin following subcutaneous administration.